GlobeNewswire Inc.Mar 9, 7:00 AM ET▲ Positive
The company announced robust clinical validation data from a large prospective multicenter study (912 patients across 30 centers) demonstrating that its DecisionDx-Melanoma test accurately predicts sentinel lymph node positivity and identifies low-risk patients with favorable outcomes. The results show strong clinical differentiation from existing staging criteria and support expanded clinical utility, which should strengthen market positioning and support clinical adoption.